Early Brief Treatment with Losartan plus Mycophenolate Mofetil Provides Lasting Renoprotection in a Renal Ablation Model

American Journal of Nephrology

Volumn 32, Issue 2, 2010, Pages 95-102

  Fujihara, Clarice Kazue ^a   Vieira, Jose Mauro ^a   Sena, Claudia Ramos ^a   Ventura, Bianca Helena ^a   Malheiros, Denise Maria ^a   Zatz, Roberto ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Angiotensin II; Chronic kidney disease; Losartan; Mycophenolate mofetil; Nephropathy progression

Indexed keywords

ALBUMIN; LOSARTAN; MYCOPHENOLATE MOFETIL; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIINFLAMMATORY AGENT; DRUG DERIVATIVE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PROTECTIVE AGENT;

ADULT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE MONITORING; BODY WEIGHT; CELL INFILTRATION; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; GLOMERULOSCLEROSIS; IMMUNODIFFUSION; IMMUNOHISTOCHEMISTRY; KIDNEY INTERSTITIUM; KIDNEY MASS; MALE; MORPHOMETRY; NONHUMAN; PRIORITY JOURNAL; RAT; RENAL ABLATION; RENAL PROTECTION; URINALYSIS; ALBUMINURIA; ANIMAL; BLOOD PRESSURE; CHRONIC DISEASE; DISEASE MODEL; DRUG COMBINATION; DRUG EFFECT; KIDNEY DISEASE; MACROPHAGE; NEPHRECTOMY; PATHOLOGY; PATHOPHYSIOLOGY; RAT STRAIN; TIME;

ALBUMINURIA; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; ANTI-INFLAMMATORY AGENTS; BLOOD PRESSURE; CHRONIC DISEASE; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; KIDNEY DISEASES; LOSARTAN; MACROPHAGES; MALE; MYCOPHENOLIC ACID; NEPHRECTOMY; PROTECTIVE AGENTS; RATS; RATS, INBRED STRAINS; TIME FACTORS;

EID: 77953335239     PISSN: 02508095     EISSN: 14219670     Source Type: Journal    
DOI: 10.1159/000315137     Document Type: Article

References (22)

1. Anderson S, Rennke HG, Brenner BM: Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Invest 1986; 77: 1993-2000.
2. Fujihara CK, Malheiros DMAC, Zatz R, Noronha IL: Mycophenolate mofetil attenuates renal injury in the rat remnant kidney. Kidney Int 1998; 54: 1510-1519.
3. Fujihara CK, Malheiros DM, Zatz R: Losartan- hydrochlorothiazide association promotes lasting blood pressure normalization and completely arrests long-term renal injury in the 5/6 ablation model. Am J Physiol Renal Physiol 2007; 292:F1810-F1818.
4. Floege J, Alpers CE, Burns MW, Pritzl P, Gordon K, Couser WG, Johnson RJ: Glomerular cells, extracellular matrix accumulation, and the development of glomerulosclerosis in the remnant kidney model. Lab Invest 1992; 66: 485-497.
5. Kliem V, Johnson RJ, Alpers CE, Yoshimura A, Couser WG, Koch KM, Floege J: Mechanisms involved in the pathogenesis of tubulointerstitial fibrosis in 5/6-nephrectomized rats. Kidney Int 1996; 49: 666-678.
6. Romero F, Rodriguez-Iturbe B, Parra G, Gonzalez L, Herrera-Acosta J, Tapia E: Mycophenolate mofetil prevents the progressive renal failure induced by 5/6 renal ablation in rats. Kidney Int 1999; 55: 945-955.
7. Yang N, Wu LL, Nikolic-Paterson DJ, Ng YY, Yang WC, Mu W, Gilbert RE, Cooper ME, Atkins RC, Lan HY: Local macrophage and myofibroblast proliferation in progressive renal injury in the rat remnant kidney. Nephrol Dial Transplant 1998; 13: 1967-1974.
8. Lafayette RA, Mayer G, Park SK, Meyer TW: Angiotensin II receptor blockade limits glomerular injury in rats with reduced renal mass. J Clin Invest 1992; 90: 766-771.
9. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy: the Collaborative Study Group. N Engl J Med 1993; 329: 1456-1462.
10. Maschio G, Alberti D, Janin G, Locatelli F, Mann JF, Motolese M, Ponticelli C, Ritz E, Zucchelli P: Effect of the angiotensin-converting- enzyme inhibitor benazepril on the progression of chronic renal insufficiency: the Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med 1996; 334: 939-945.
11. Wu LL, Cox A, Roe CJ, Dziadek M, Cooper ME, Gilbert RE: Transforming growth factor beta 1 and renal injury following subtotal nephrectomy in the rat: role of the renin-angiotensin system. Kidney Int 1997; 51: 1553-1567.
12. Fujihara CK, Noronha IL, Malheiros DMAC, Antunes GR, Oliveira IB, Zatz R: Combined mycophenolate mofetil and losartan therapy arrests established injury in the remnant kidney. J Am Soc Nephrol 2000; 11: 283-290.
13. Goncalves AR, Fujihara CK, Mattar AL, Malheiros DMAC, Noronha IL, De Nucci G, Zatz R: Renal expression of COX-2, ANG II, and AT1 receptor in remnant kidney: strong renoprotection by therapy with losartan and a nonsteroidal anti-inflammatory. Am J Physiol Renal Physiol 2004; 286:F945-F954.
14. Yamamoto M, Fukui M, Shou I, Wang LN, Sekizuka K, Suzuki S, Shirato I, Tomino Y: Effects of treatment with angiotensin-converting enzyme inhibitor (ACEI) or angiotensin II receptor antagonist (AIIRA) on renal function and glomerular injury in subtotal nephrectomized rats. J Clin Lab Anal 1997; 11: 53-62.
15. Meyer TW, Anderson S, Rennke HG, Brenner BM: Reversing glomerular hypertension stabilizes established glomerular injury. Kidney Int 1987; 31: 752-759.
16. Jepsen FL, Mortensen PB: Interstitial fibrosis of the renal cortex in minimal change lesion and its correlation with renal function: a quantitative study. Virchows Arch A Pathol Anat Histol 1979; 383: 265-270.
17. Wallenstein S, Zucker CL, Fleiss JL: Some statistical methods useful in circulation research. Circ Res 1980; 47: 1-9.
18. Fujihara CK, Sena CR, Malheiros DM, Mattar AL, Zatz R: Short-term nitric oxide inhibition induces progressive nephropathy after regression of initial renal injury. Am J Physiol Renal Physiol 2006; 290:F632-F640.
19. Badid C, Vincent M, McGregor B, Melin M, Hadj-Aissa A, Veysseyre C, Hartmann DJ, Desmouliere A, Laville M: Mycophenolate mofetil reduces myofibroblast infiltration and collagen III deposition in rat remnant kidney. Kidney Int 2000; 58: 51-61.
20. Hauser IA, Renders L, Radeke HH, Sterzel RB, Goppelt-Struebe M: Mycophenolate mofetil inhibits rat and human mesangial cell proliferation by guanosine depletion. Nephrol Dial Transplant 1999; 14: 58-63.
21. Remuzzi G, Zoja C, Gagliardini E, Corna D, Abbate M, Benigni A: Combining an antiproteinuric approach with mycophenolate mofetil fully suppresses progressive nephropathy of experimental animals. J Am Soc Nephrol 1999; 10: 1542-1549.
22. Rodriguez-Iturbe B, Quiroz Y, Nava M, Bonet L, Chavez M, Herrera-Acosta J, Johnson RJ, Pons HA: Reduction of renal immune cell infiltration results in blood pressure control in genetically hypertensive rats. Am J Physiol Renal Physiol 2002; 282:F191-F201.